Zacks: Analysts Anticipate Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Will Announce Earnings of -$0.28 Per Share

Analysts expect that Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPHGet Rating) will report earnings of ($0.28) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Reviva Pharmaceuticals’ earnings. Reviva Pharmaceuticals posted earnings of ($0.10) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 180%. The company is expected to issue its next earnings report on Monday, January 1st.

On average, analysts expect that Reviva Pharmaceuticals will report full-year earnings of ($0.99) per share for the current year, with EPS estimates ranging from ($1.22) to ($0.76). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.83) per share, with EPS estimates ranging from ($0.93) to ($0.73). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Reviva Pharmaceuticals.

Separately, HC Wainwright assumed coverage on Reviva Pharmaceuticals in a report on Monday, January 24th. They issued a “buy” rating and a $10.00 price target on the stock.

Shares of NASDAQ RVPH traded up $0.02 during mid-day trading on Friday, hitting $2.09. The company had a trading volume of 24,533 shares, compared to its average volume of 42,420. The stock has a market cap of $31.62 million, a price-to-earnings ratio of -3.73 and a beta of 0.08. Reviva Pharmaceuticals has a 12 month low of $1.53 and a 12 month high of $6.07. The firm’s 50 day simple moving average is $2.04 and its two-hundred day simple moving average is $2.63.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Reviva Pharmaceuticals during the 4th quarter valued at $27,000. BlackRock Inc. grew its holdings in shares of Reviva Pharmaceuticals by 82.7% in the 3rd quarter. BlackRock Inc. now owns 33,470 shares of the company’s stock worth $136,000 after acquiring an additional 15,152 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Reviva Pharmaceuticals by 13.6% in the 3rd quarter. Geode Capital Management LLC now owns 76,964 shares of the company’s stock worth $313,000 after acquiring an additional 9,240 shares during the last quarter. Hedge funds and other institutional investors own 17.22% of the company’s stock.

About Reviva Pharmaceuticals (Get Rating)

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentionÂ-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.

See Also

Get a free copy of the Zacks research report on Reviva Pharmaceuticals (RVPH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Reviva Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reviva Pharmaceuticals and related companies with's FREE daily email newsletter.